Does the funding source influence the results in economic evaluations?: A case study in bisphosphonates for the treatment of osteoporosis

PharmacoEconomics

Volumn 28, Issue 4, 2010, Pages 295-306

  Fleurence, Rachael L ^a   Spackman, D Eldon ^b   Hollenbeak, Christopher ^c  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Bisphosphonates, therapeutic use; Cost utility; Osteoporosis, treatment

Indexed keywords

ALENDRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; RISEDRONIC ACID;

ARTICLE; CANADA; CASE STUDY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DENMARK; DRUG INDUSTRY; ECONOMIC EVALUATION; FUNDING; GEOGRAPHIC DISTRIBUTION; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MEDICAL LITERATURE; OSTEOPOROSIS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY CONTROL; RESOURCE MANAGEMENT; SCORING SYSTEM; SENSITIVITY ANALYSIS; SPAIN; SWEDEN; SYSTEMATIC ERROR; SYSTEMATIC REVIEW; UNITED KINGDOM; UNITED STATES;

EID: 77949414359     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11530530-000000000-00000     Document Type: Article

References (47)

1. Taylor RS, Drummond MF, Salkeld G, et al. Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle. BMJ 2004 Oct 23; 329 (7472): 972-975
2. National Institute for Health and Clinical Excellence [online]. Guide to the methods of technology appraisal. London: NICE, 2008 Jun
3. Academy of Managed Care Pharmacy [online]. Available from URL: http://www.fmcpnet.org/data/resource/For mat~Version-2-1~Final-Final.pdf [Accessed 2009 Dec 16]
4. Neumann PJ. Evidence-based and value-based formulary guidelines. Health Aff (Millwood) 2004 Jan-Feb; 23 (1): 124-134
5. Tufts Medical Center. The CEA registry [online]. Available from URL: https://research.tufts-nemc.org/cear/default. aspx [Accessed 2009 Dec 15]
6. Bell CM, Urbach DR, Ray JG, et al. Bias in published cost effectiveness studies: systematic review. BMJ 2006 Mar 25; 332 (7543): 699-703
7. Fleurence RL, Iglesias CP, Johnson JM. The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature. Pharmacoeconomics 2007; 25 (11): 913-933
8. Eichler HG, Kong SX, Gerth WC, et al. Use of costeffectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 2004 Sep-Oct; 7 (5): 518-528
9. Evans C, Tavakoli M, Crawford B. Use of quality adjusted life years and life years gained as benchmarks in economic evaluations: a critical appraisal. Health Care Manag Sci 2004 Feb; 7 (1): 43-49
10. Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992 Feb 15; 146 (4): 473-481
11. Neumann PJ, Greenberg D, Olchanski NV, et al. Growth and quality of the cost-utility literature, 1976-2001. Value Health 2005 Jan-Feb; 8 (1): 3-9
12. Owens DK. Interpretation of cost-effectiveness analyses. J Gen Intern Med 1998 Oct; 13 (10): 716-717
13. Neumann PJ, Stone PW, Chapman RH, et al. The quality of reporting in published cost-utility analyses, 1976-1997. Ann Intern Med 2000 Jun 20; 132 (12): 964-972
14. Ankjaer-Jensen A, Johnell O. Prevention of osteoporosis: cost-effectiveness of different pharmaceurical treatments. Osteoporos Int 1996; 6 (4): 265-275
15. Aursnes I, Storvik G, Gasemyr J, et al. A Bayesian analysis of bisphosphonate effects and cost-effectiveness in postmenopausal osteoporosis. Pharmacoepidemiol Drug Saf 2000; 9 (6): 501-509
16. Buckley LM, Hillner BE.Acost effectiveness analysis of calcium and vitamin D supplementation, etidronate, and alendronate in the prevention of vertebral fractures in women treated with glucocorticoids. J Rheumatol 2003 Jan; 30 (1): 132-138
17. Francis RM, Anderson FH, Torgerson DJ. A comparison of the effectiveness and cost of treatment for vertebral fractures in women. Br J Rheumatol 1995 Dec; 34 (12): 1167-1171
18. Rodriguez Escolar C, Fidalgo Garcia ML, Rubio Cerbrian S. A cost-effectiveness analysis of alendronate compared to placebo in the prevention of hip fracture. Atencion Primaria 1999 Oct; 24 (7): 390-396
19. Rosner AJ, Grima DT, Torrance GW, et al. Cost effectiveness of multi-therapy treatment strategies in the prevention of vertebral fractures in postmenopausal women with osteoporosis. Pharmacoeconomics 1998 Nov; 14 (5): 559-573
20. Borgstrom F, Johnell O, Jonsson B, et al. Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden. Bone 2004 Jun; 34 (6): 1064-1071
21. Brown MA, Bradlow J,Gray AM. Cost effectiveness of bone density measurements. J Br Menopause Soc 2001 Sep; 7 (3): 130-135
22. Christensen PM, Brixen K, Gyrd-Hansen D, et al. Costeffectiveness of alendronate in the prevention of osteoporotic fractures in Danish women. Basic Clin Pharmacol Toxicol 2005 May; 96 (5): 387-396
23. Coyle D, Cranney A, Lee KM, et al. Cost effectiveness of nasal calcitonin in postmenopausal women: use of Cochrane Collaboration methods for meta-analysis within economic evaluation. Pharmacoeconomics 2001; 19 (5 Pt 2): 565-575
24. Grima DT, Burge RT, Becker DL, et al. Short-term cost-effectiveness of bisphosphonate therapies for postmenopausal osteoporotic women at high risk of fracture. P T 2002 Sep; 27 (9): 448-455
25. Hart WM, Rubio-Terres C, Burrell A, et al. Pharmacoeconomic analysis of the treatment of postmenopausal osteoporosis with risedronate or alendronate. Rev Esp Enferm Metab Oseas 2002; 11 (3): 97-104
26. Iglesias CP, TorgersonDJ, Bearne A, et al. The cost utility of bisphosphonate treatment in established osteoporosis. QJM 2002 May; 95 (5): 305-311
27. Johnell O, Jonsson B, Jonsson L, et al. Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics 2003; 21 (5): 305-314
28. Kanis JA, Borgstrom F, Johnell O, et al. Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women. Osteoporos Int 2004 Nov; 15 (11): 862-871
29. Kanis JA, Brazier JE, Stevenson M, et al. Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 2002; 6 (29): 1-146
30. Mobley LR, Hoerger TJ, Wittenborn JS, et al. Costeffectiveness of osteoporosis screening and treatment with hormone replacement therapy, raloxifene, or alendronate. Med Decis Making 2006 Mar-Apr; 26 (2): 194-206
31. Pfister AK, Welch CA, Lester MD, et al. Cost-effectiveness strategies to treat osteoporosis in elderly women. South Med J 2006 Feb; 99 (2): 123-131
32. Schousboe JT, Ensrud KE, Nyman JA, et al. Potential cost-effective use of spine radiographs to detect vertebral deformity and select osteopenic post-menopausal women for amino-bisphosphonate therapy. Osteoporos Int 2005 Dec; 16 (12): 1883-1893
33. Schousboe JT, Ensrud KE, Nyman JA, et al. Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women. J Am Geriatr Soc 2005 Oct; 53 (10): 1697-1704
34. Schousboe JT,Nyman JA,Kane RL, et al. Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. Ann Intern Med 2005 May 3; 142 (9): 734-741
35. Solomon DH, Kuntz KM. Should postmenopausal women with rheumatoid arthritis who are starting corticosteroid treatment be screened for osteoporosis? A cost-effectiveness analysis. Arthritis Rheum 2000 Sep; 43 (9): 1967-1975
36. Stevenson M, Jones ML, De Nigris E, et al. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 2005 Jun; 9 (22): 1-160
37. Hartmann M, Knoth H, Schulz D, et al. Industry-sponsored economic studies in oncology vs studies sponsored by nonprofit organisations. Br J Cancer 2003 Oct 20; 89 (8): 1405-1408
38. Friedberg M, Saffran B, Stinson TJ, et al. Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA 1999 Oct 20; 282 (15): 1453-1457
39. HartmannM, Knoth H, Schulz D, et al. Industry-sponsored economic studies in critical and intensive care versus studies sponsored by nonprofit organizations. J Intensive Care Med 2003 Sep-Oct; 18 (5): 265-268
40. Baker CB, Johnsrud MT, Crismon ML, et al. Quantitative analysis of sponsorship bias in economic studies of antidepressants. Br J Psychiatry 2003 Dec; 183: 498-506
41. Miners AH, Garau M, Fidan D, et al. Comparing estimates of cost effectiveness submitted to the National Institute for Clinical Excellence (NICE) by different organisations: retrospective study. BMJ 2005 Jan 8; 330 (7482): 65
42. Braithwaite RS, Meltzer DO, King Jr JT, et al. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care 2008 Apr; 46 (4): 349-356
43. Luce BR, Mauskopf J, Sloan FA, et al. The return on investment in health care: from 1980 to 2000. Value Health 2006 May-Jun; 9 (3): 146-156
44. Coyle D, Tosteson AN. Towards a reference case for economic evaluation of osteoporosis treatments. J Rheumatol Suppl 2003 Dec; 68: 31-36
45. Sculpher M, Fenwick E, Claxton K. Assessing quality in decision analytic cost-effectiveness models: a suggested framework and example of application. Pharmacoeconomics 2000 May; 17 (5): 461-477
46. Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices - Modeling Studies. Value Health 2003 Jan-Feb; 6 (1): 9-17
47. Lipsitz SR, Fitzmaurice GM, Orav EJ, et al. Performance of generalized estimating equations in practical situations. Biometrics 1994 Mar; 50 (1): 270-278